Skip to main content

Drug Targeting Strategies in Cancer Treatment: An Overview

Notice

The full text article is available externally.

View from original source.

Classic chemotherapy has little or no specificity for cancer cells, normally resulting in low accumulation at the tumor region (inefficacy), and in severe side effects (toxicity). This challenge has resulted in the development of several delivery strategies for chemotherapy agents to improve their concentration at the tumor site, simultaneously increasing their anticancer efficacy, while reducing the associated adverse systemic effects. In this work, the potential of drug delivery strategies involving the use of nanocarriers for controlling the biodistribution of antitumor drugs is deeply revised: passive targeting (through the enhanced permeability and retention effect, EPR effect) and active targeting (including stimuli-sensitive carriers and ligand-mediated delivery). Special attention will be also focussed on the recent approaches for overcoming multi-drug resistance. Finally, a general view of the problem of “nanotoxicity” in cancer treatment is also given.





Keywords: 5-fluorouracil; Active targeting; Aptamer-Mediated Targeting; CREKA; Caelyx; Cremophor; DAOY; DOX-SLNs; Doxil; Doxorubicin; EGFR; Flow cytometry; Folate Receptor Targeting; Genexol-PM; H2009; HeLa; HepG2; Integrin-Mediated Targeting; Inulin multi-methacrylate (IMMA); LNCaP xenograft; Low frequency ultrasound; Magnetic Drug Targeting; Myocet; PE38KDEL; PEGylation; PLA-PEG; PSMA; Peptide-Mediated Targeting; Pseudomonas; TRAIL immunotherapy; Thermo-sensitive magnetoliposomes; Transferrin Receptor Targeting; Ultrasound-Mediated Drug Delivery; acute myeloid leukemia; antitumor activity; asialoglycoprotein; cancer treatment; caprolactone; chemotherapy agent; colloidal drug delivery systems; confocal microscopy; controlled release; drug carrier; fibronectin; fluorescence microscopic; hyperthermia; metalloproteinase-2; methotrexate; monoclonal antibodies; mononuclear phagocyte system; multi-drug resistance; nanotoxicity; opsonins; paclitaxel; paclitaxel prodrug; passive targeting; prodrug therapy; reticuloendothelial system; tamoxifen; tariquidar; vasoactive intestinal peptide

Document Type: Research Article

Publication date: January 1, 2011

More about this publication?
  • The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

    The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

    Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Call for Papers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content